Dawn of a New Era: World's First Dual-Payload Cancer Drug Enters Trials

SUZHOU, China – February 09, 2026 – The global race to develop more potent and precise cancer treatments has reached a pivotal milestone. Chengdu Kanghong Pharmaceutical Group's innovative drug, KH815, has officially become the world's first dual-payload antibody-drug conjugate (ADC) to enter human clinical trials, marking a significant leap forward in targeted oncology. This achievement, which saw the drug advance to clinical stage 1.5 months ahead of schedule, was made possible through a critical partnership with the global contract development and manufacturing organization (CDMO), BioDlink.

The therapy received clinical trial authorization from Australia's Human Research Ethics Committee (HREC) on March 21, 2025, followed by approval in China on April 15, 2025. The Phase 1 study is now underway, evaluating the safety and preliminary efficacy of KH815 in patients with advanced solid tumors. The entry of this first-in-class drug into the clinic not only represents a potential paradigm shift for treating complex cancers but also highlights the power of strategic collaboration in navigating the immense complexities of modern drug development.

A New Frontier in Targeted Therapy

Antibody-drug conjugates have long been hailed as "magic bullets" for their ability to deliver potent toxins directly to cancer cells while sparing healthy tissue. However, tumors are notoriously clever, often developing resistance to a single mode of attack. Dual-payload ADCs represent the next evolutionary step, designed to outsmart this resistance by delivering two distinct cytotoxic agents on a single antibody.

KH815 exemplifies this advanced approach. The drug targets TROP2, a protein commonly overexpressed on the surface of various aggressive solid tumors. Attached to its antibody backbone via a sophisticated branched linker are two different payloads: a topoisomerase I inhibitor and an RNA polymerase II inhibitor. By deploying two separate mechanisms of action simultaneously, KH815 aims to deliver a synergistic, one-two punch that can be more effective than single-payload drugs, particularly against heterogeneous tumors or those that have become resistant to other treatments. Preclinical studies have shown its potential, demonstrating superior tumor inhibition even in models resistant to existing therapies.

The development of such a complex molecule is a monumental scientific and manufacturing challenge. The field is bustling with activity, with major players like Sutro Biopharma, Debiopharm, and Innovent all pursuing similar dual-warhead strategies. However, Kanghong's KH815 has won the race to the clinic, setting a new benchmark and validating a therapeutic concept that could unlock new possibilities for patients with hard-to-treat cancers.

The Engine of Innovation: Partnership Accelerates Breakthrough

Bringing a first-in-class molecule like KH815 from the laboratory to human trials at an accelerated pace required more than just innovative science; it demanded exceptional execution in development and manufacturing. This is where Kanghong's CDMO partner, BioDlink, played an indispensable role. The Suzhou-based company received formal recognition from Kanghong for its critical contributions across the entire development lifecycle.

BioDlink was tasked with process and analytical method development, formulation research, and manufacturing—all under aggressive timelines and with limited availability of starting materials. The complexity of a dual-payload ADC necessitates exquisite control over the manufacturing process, particularly in managing the precise drug-to-antibody ratio (DAR) for both payloads to ensure consistency, safety, and efficacy.

Leveraging its specialized expertise in bioconjugates, BioDlink delivered a robust and scalable manufacturing solution. The company's proprietary technologies, including its GL-DisacLink® site-specific conjugation platform, were instrumental. This advanced technology facilitates a more stable and uniform ADC product, simplifying workflows and reducing production costs. Combined with its integrated "one-base, end-to-end" platform in Suzhou, which co-locates all stages of development and manufacturing, BioDlink was able to streamline the path to the clinic, ultimately completing all activities 1.5 months ahead of schedule and earning high praise from its partner.

Navigating a Global Regulatory Gauntlet

Securing regulatory clearance for a novel therapeutic, especially one that defines a new class of drug, is a formidable challenge. The successful and swift clinical trial authorizations for KH815 in both Australia and China underscore a well-executed global regulatory strategy and the growing sophistication of China's biopharmaceutical ecosystem.

Australia, with its established framework for fast-tracking promising new medicines, provided an efficient pathway for initiating the first-in-human studies. The approval from the HREC in March 2025 allowed the program to gain critical early momentum. Shortly after, the green light from China's National Medical Products Administration (NMPA) in April 2025 confirmed the drug's potential and opened a second major front for clinical investigation.

This dual-country approval highlights the increasing ability of Chinese firms to operate on the international stage, meeting the stringent quality and safety standards of multiple regulatory bodies. It also reflects the ongoing reforms within China's NMPA, which has cultivated an environment that encourages and accelerates domestic innovation. The successful navigation of these two distinct regulatory systems for a complex biologic like KH815 demonstrates a high level of technical and strategic maturity.

A Strategic Bet on Advanced Biologics

For Kanghong Pharmaceutical, the advancement of KH815 is not an isolated success but a cornerstone of a deliberate corporate strategy to become a leader in innovative global medicines. Founded in 1996, the Sichuan-based company built its reputation on the success of drugs like Conbercept, a blockbuster ophthalmic therapy that was one of China's first homegrown biologic innovators to gain international recognition.

Building on that foundation, Kanghong has been decisively pivoting its R&D pipeline toward next-generation modalities, with a significant focus on antibody-drug conjugates and gene therapies. The development of a first-in-class dual-payload ADC is a bold and resource-intensive endeavor that signals the company's ambition to compete at the cutting edge of oncology.

This strategic investment in high-risk, high-reward innovation, supported by partnerships with expert organizations like BioDlink, positions Kanghong not just as a domestic leader but as an emerging force in the global biopharmaceutical landscape. The progress of KH815 through clinical trials will be watched closely by the entire industry, as its success could pave the way for a new class of powerful cancer therapies and further cement China's role as a vital hub for drug discovery and development.